CenterBook Partners LP Grows Stock Holdings in Charles River Laboratories International, Inc. $CRL

CenterBook Partners LP boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 534.0% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 23,794 shares of the medical research company’s stock after buying an additional 20,041 shares during the period. CenterBook Partners LP’s holdings in Charles River Laboratories International were worth $3,723,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of CRL. Vanguard Group Inc. raised its stake in Charles River Laboratories International by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,839,743 shares of the medical research company’s stock valued at $913,686,000 after purchasing an additional 27,989 shares during the period. Ariel Investments LLC grew its holdings in Charles River Laboratories International by 28.6% during the 2nd quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after buying an additional 314,572 shares in the last quarter. Invesco Ltd. grew its holdings in Charles River Laboratories International by 11.6% during the 2nd quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock valued at $187,712,000 after buying an additional 128,785 shares in the last quarter. Bank of America Corp DE raised its position in shares of Charles River Laboratories International by 29.2% during the second quarter. Bank of America Corp DE now owns 1,026,013 shares of the medical research company’s stock valued at $155,677,000 after buying an additional 232,020 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Charles River Laboratories International by 5.9% in the second quarter. Sei Investments Co. now owns 714,688 shares of the medical research company’s stock worth $108,440,000 after buying an additional 39,959 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $158.28 on Thursday. The stock’s fifty day moving average is $201.46 and its 200 day moving average is $179.44. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $228.88. The firm has a market capitalization of $7.79 billion, a PE ratio of -101.46, a PEG ratio of 4.80 and a beta of 1.63. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.10 and a current ratio of 1.37.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The company had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. During the same period last year, the company earned $2.66 earnings per share. Charles River Laboratories International’s revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Morgan Stanley set a $185.00 price objective on Charles River Laboratories International in a research report on Monday, December 1st. Wall Street Zen raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Barclays increased their price target on Charles River Laboratories International from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Finally, Mizuho set a $215.00 price objective on Charles River Laboratories International in a research note on Friday, January 9th. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus target price of $209.46.

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Company forecasts stronger 2026 profit driven by improving demand for drug‑development services, supporting the view that revenues and margins should recover. Charles River forecasts upbeat 2026 profit on improved demand for drug development services
• Positive Sentiment: Q4 results beat expectations: revenue ~ $994M and EPS $2.39 beat consensus, and margins expanded — a near‑term fundamental positive. Charles River Laboratories (NYSE: CRL) beats Q4 CY2025 sales expectations
• Positive Sentiment: Management projects up to ~9% EPS growth for 2026, citing a new CEO, targeted acquisitions and cost‑savings initiatives to expand margins — a constructive catalyst for longer‑term earnings. Charles River projects up to 9% EPS growth in 2026 as new CEO, acquisitions, and cost savings drive margin expansion
• Neutral Sentiment: Company announced executive appointments that support the strategic shift; impact depends on execution of cost and M&A plans. Charles River Laboratories Announces Executive Appointments
• Neutral Sentiment: Detailed Q4 earnings call transcript and slide deck are available for investors to assess pipeline, book‑to‑bill trends and 2026 assumptions. Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Organic growth fell across all segments and revenue was down ~0.8% year‑over‑year, raising questions about near‑term demand recovery and the pace of margin improvement. CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: EPS declined versus the prior year and the firm still showed a negative net margin in the quarter, which may keep some investors cautious despite the beat. Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.